Saltar al contenido principal
xMedica

NCT07685808ClinicalTrials.gov

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

A Phase 2, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Olatorepatide, a GLP-1/GIP Receptor Agonist, With Different Doses and Drug-Titration Algorithms in Participants Living With Overweight or Obesity

En reclutamientoAdmite participantes ahora, según el registro.
Contactar con este estudio

En resumen

This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing…

Fase 2360 participantes buscados22 centros1 país

Categorías

Registrado en 1 registro

Un mismo estudio puede estar registrado en varios registros. Lo mostramos una sola vez y enlazamos con todos los registros que tenemos.

La información del ensayo se muestra tal como la publicó el registro, en su idioma original.

¿Le interesa este estudio?

Iniciar sesión o cree una cuenta para registrar su interés y seguir este estudio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-07-06; recorded start 2026-07-28
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 264 other studies in this databaseCounted from the lead sponsor named in the record (Regeneron Pharmaceuticals)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm15/15

    Active-comparator control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre0/8

    Single site, or site count not stated

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study: 360 participants (target), run at 22 sites.

How this score is built
  • Enrolment25/40

    360 participants (target)

  • Site count0/25

    Site count not stated in the record

  • Country count0/15

    Country count not stated in the record

  • Planned duration6/10

    Planned over about 18 months

  • Sponsor scale9/10

    Regeneron Pharmaceuticals has led 250 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Resumen

This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing side effects, as well as how the drug is processed in the body by participants with overweight or obesity but do not have diabetes. The study is looking at: * What side effects the study drug might cause * How much study drug is in the blood at different times * How well the study drug works * What effects the study drug may have on the body at different dosing schedules * If the body makes antibodies to the study drug as this may cause the study drug to not work as well

Afecciones

  • Overweight or Obesity

Elegibilidad

Elegibilidad
SexoTodos
Edades18 Years – Sin máximo
Voluntarios sanosNo

Elegibilidad tal como figura en el registro

Key Inclusion Criteria: 1. Body Mass Index (BMI) ≥30.0 kg/m\^2 to \<45.0 kg/m\^2 at screening OR 2. BMI ≥27.0 kg/m\^2 at screening with at least 1 of the following weight-related co-morbidities: Hypertension, Dyslipidemia, Prediabetes, established Obstructive Sleep Apnea (OSA), established Coronary Artery Disease (CAD), Heart failure, established cerebrovascular disease as described in the protocol Key Exclusion Criteria: 1. Previous or current diagnosis of Type 1 or Type 2 diabetes at screening 2. Change in body weight \>5 kg within approximately 3 months before screening as described in the protocol 3. Bariatric surgery, including any procedures to revise, reverse, or remove any previous bariatric surgery interventions as described in the protocol 4. History of acute or chronic pancreatitis, cholecystitis, or symptomatic gallbladder stones 5. History or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply

Elegibilidad en frases sencillas

Los criterios de este registro aún no se han desglosado en frases separadas. El texto del registro anterior está completo y es la versión autorizada.

Diseño del estudio

Diseño del estudio
Tipo de estudioDe intervención
FaseFase 2
AsignaciónAleatorizado
Modelo de intervenciónPARALLEL
Propósito principalTREATMENT
EnmascaramientoQUADRUPLE (4)
Inscripción360 participantes buscados

Patrocinador y colaboradores

  • Regeneron Pharmaceuticals Patrocinador

Grupos e intervenciones

  • Olatorepatide arm 1EXPERIMENTAL
  • Olatorepatide arm 2EXPERIMENTAL
  • Olatorepatide arm 3EXPERIMENTAL
  • Olatorepatide arm 4EXPERIMENTAL
  • Olatorepatide arm 5EXPERIMENTAL
  • Matching Placebo arm 6ACTIVE_COMPARATOR

Intervenciones

  • Fármaco Olatorepatide

    Administered per the protocol

  • Fármaco Placebo

    Administered per the protocol

Variables de resultado

  1. Variable de resultado principal

    Occurrence of Treatment-Emergent Adverse Events (TEAEs)

    Plazo Up to approximately 60 weeks

  2. Variable de resultado principal

    Severity of TEAEs

    Plazo Up to approximately 60 weeks

  3. Variable de resultado principal

    Percent change in body weight

    Plazo From baseline to week 52

  4. Variable de resultado secundaria

    Olatorepatide concentrations

    Plazo Up to approximately 60 weeks

  5. Variable de resultado secundaria

    Occurrence of Anti-Drug Antibody (ADA) to olatorepatide

    Plazo Up to approximately 52 weeks

  6. Variable de resultado secundaria

    Magnitude of ADA to olatorepatide

    Plazo Up to approximately 52 weeks

Fechas

Fechas
Fecha de inicio28 de julio de 2026 (real)
Finalización principal21 de enero de 2028 (estimada)
Finalización21 de enero de 2028 (estimada)
Primera publicación6 de julio de 2026 (real)
Última actualización18 de noviembre de 2026
Resultados publicadosNo indicado en el registro
Estado verificado por última veznoviembre de 2026

Real significa que el evento ocurrió. Estimada significa que el patrocinador lo prevé. Ambas cosas significan algo distinto.

Ubicaciones

22 centros están en reclutamiento

United States

United States
CentroCiudadEstado o regiónEstado
Flourish Research, Ravenswood RheumatologyChicagoIllinoisEn reclutamiento
Charter Research LLC - ChicagoChicagoIllinoisEn reclutamiento
Alliance for Multispecialty Research (AMR) Clinical MiamiDoralFloridaEn reclutamiento
AMR Clinical - Fort MyersFort MyersFloridaEn reclutamiento
Tribe Clinical ResearchGreenvilleSouth CarolinaEn reclutamiento
AGA Clinical TrialsHialeahFloridaEn reclutamiento
Flourish Research, Nature Coast Clinical ResearchInvernessFloridaEn reclutamiento
Flourish Research, Jacksonville Center for Clinical ResearchJacksonvilleFloridaEn reclutamiento
AMR Clinical - LexingtonLexingtonKentuckyEn reclutamiento
K2 Medical Research Maitland LLC, Main OfficeMaitlandFloridaEn reclutamiento
AMR Clinical - MobileMobileAlabamaEn reclutamiento
NYC Research IncNew YorkNew YorkEn reclutamiento
AMR Clinical - Chicago Oak BrookOak BrookIllinoisEn reclutamiento
Velocity Clinical Research - OmahaOmahaNebraskaEn reclutamiento
Rochester Clinical ResearchRochesterNew YorkEn reclutamiento
Flourish Research, Legacy Oaks TowerSan AntonioTexasEn reclutamiento
The IMA Group, IMA Clinical Research St. PetersburgSt. PetersburgFloridaEn reclutamiento
Charter Research LLC - The VillagesThe VillagesFloridaEn reclutamiento
Diablo Clinical Research - Flourish ResearchWalnut CreekCaliforniaEn reclutamiento
Chase Medical ResearchWaterburyConnecticutEn reclutamiento
AMR Clinical WichitaWichitaKansasEn reclutamiento
Clinical Site Partners, LLC DBA Flourish ResearchWinter ParkFloridaEn reclutamiento

Documentos del estudio

No hay documentos enlazados en este registro.

Cambios a lo largo del tiempo

  1. 18 de noviembre de 2026

    Centro añadido

    1 site added (22 total)

    2122

  2. 13 de octubre de 2026

    Centro añadido

    3 sites added (21 total)

    1821

  3. 29 de septiembre de 2026

    Centro añadido

    13 sites added (18 total)

    518

  4. 20 de agosto de 2026

    Estado modificado

    Status changed from Not yet recruiting to Recruiting

    NOT_YET_RECRUITINGRECRUITING

  5. 20 de agosto de 2026

    Reclutamiento abierto

    Recruitment opened

    NOT_YET_RECRUITINGRECRUITING

  6. 20 de agosto de 2026

    Centro añadido

    5 sites added (5 total)

    05